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PURPOSE: The prospective PCM301 trial randomized 413 men with low risk
prostate cancer to partial gland ablation with vascular targeted photodynamic
therapy in 207 and active surveillance in 206. Two-year outcomes were reported
previously. We report 4-year rates of intervention with radical therapy and further
assess efficacy with biopsy results.
MATERIALS AND METHODS: Prostate biopsies were mandated at 12 and 24
months. Thereafter patients were monitored for radical therapy with periodic
biopsies performed according to the standard of care at each institution. Ablation
efficacy was assessed by biopsy results overall and in field in the treated lobe or the
lobe with index cancer.
RESULTS: Conversion to radical therapy was less likely in the ablation cohort than
in the surveillance cohort, including 7% vs 32% at 2 years, 15% vs 44% at 3 years
and 24% vs 53% at 4 years (HR 0.31, 95% CI 0.21-0.46). Radical therapy triggers
were similar in the 2 arms. Cancer progression rates overall and by grade were
significantly lower in the ablation cohort (HR 0.42, 95% CI 0.29-0.59). End of study
biopsy results were negative throughout the prostate in 50% of patients after
ablation vs 14% after surveillance (risk difference 36%, 95% CI 28-44). Gleason 7
or higher cancer was less likely for ablation than for surveillance (16% vs 41%). Of
the in field biopsies 10% contained Gleason 7 cancer after ablation vs 34% after
surveillance.
CONCLUSIONS: In this randomized trial of partial ablation of low risk prostate
cancer photodynamic therapy significantly reduced the subsequent finding of
higher grade cancer on biopsy. Consequently fewer cases were converted to radical
therapy, a clinically meaningful benefit that lowered treatment related morbidity.
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